We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Diurnal Group Plc | DNL | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 27.30 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 27.30 | 27.30 |
| Top Posts |
|---|
Posted at 30/8/2022 11:27 by deanmatlazin look like STX is going to be taken for a cheap price too like DNL. What a shame! |
Posted at 30/8/2022 10:05 by bamboo2 Bonus payments from ETON over the next five years will mean Neurocrine gets DNL at near enough zero cost.There has to be a counter offer, leading to a better price for the co. |
Posted at 30/8/2022 08:43 by deanmatlazin Should be a counter bid. Too cheap at this price to be honest. no competitor and whoever bought DNL will make loads of money in coming years. I agree it should be taken over about £100m.There was an article about British companies were being bought at cheap price with current economic climate. What a shame! |
Posted at 16/8/2022 07:28 by best1467 The 100 million is unlikely Impossible but would be delighted if they can achieve the 10 next year and the 25 y/e following. when Eton originally came out with that 100 million it was suggested by DNL and the house broker to be slightly beyond reach |
Posted at 15/8/2022 10:18 by weatherman If Q2 2021 revenue from Alkindi was $0.5m, then 293% would take us to ~$2.0m revenue by Q2 2022. If they can reach $15m by end of FY, which is a big stretch, then they may well exceed the $10m target, and DNL receives $1m, plus ~$1.5m royalties. Admittedly, a lot of guess work there. |
Posted at 15/8/2022 08:46 by rgmgo Weatherman. You can also cross reference with the Diurnal sales commentary, unfortunately, and deliberately, I don't think you have quite enough disclosure to be definitive on the numbers. I have some guestimates for US alkindi sales which are half yearly rather than quarterly. 1H2022 $1.0mn, 2H2022 $1.5mn , 2022E $2.5mn(out of underlying group sales of $2.8mn), 2023E $8mn. Why the big jump in 2023? Well we know the sequential growth numbers are high and sales only really picked up momentum in 4Q2022 with the game changing Tolmar distribution deal. We also know that alkindi is Eton's biggest product so these numbers are not inconsistent with already reported $4.5mn product sales and royalties revenues for 1H2022 and the $15mn 2023E revenue commentary (they have already booked $5mn royalty licensing revenues so I am guestimating c $10mn Eton product sales. That said, please feel free to unpick the logic, iterate some different numbers. If however these expectations are close to being right, the message is a strong one. 1. The numbers are beginning to get material in the US, 2. DNL could be closing in on the next sales milestone payment (they receive $1mn from Eton when net sales exceed $100 million in a calendar year). We know from a recent Eton call that the Tolmar sales force is going through a reorganisation which may adversely impact shorter term sales but is expected to steepen longer term growth, so this will likely push the $10mn revenue milestone into calendar 2024. It is also worth reiterating that DNL only receives a tiered royalty from Eton ranging from a low double-digit to high teens percentage on net sales of Alkindi Sprinkle, so the impact is muted on the DNL reported revenues. However, if momentum is maintained there are some chunky milestones down the line, $4 million when net sales exceed $25 million in a calendar year, $7.5 million when net sales exceed $50 million in a calendar year etc. Eton believes alkindi has $100mn+ US sales potential. Alkindi US is only one part of the DNL growth story but it might provide some much needed validation of the model. If DNL can successfully negotiate the nearer term funding gap without too much dilution, long suffering shareholders may eventually get some reward. |
Posted at 13/8/2022 13:25 by best1467 Don’t forget it’s been a rapid crash in the last 6 months as with Shield DNL have possibly approached the money and Equity markets and been knocked back then in come the informed shorters and we end up here |
Posted at 12/8/2022 19:17 by bamboo2 best1467, I see, thanks. £100m or $100m?Looking at the trigger payments, I can see why you have that kind of figure in mind. $1 million when net sales exceed $10 million in a calendar year $4 million when net sales exceed $25 million in a calendar year $7.5 million when net sales exceed $50 million in a calendar year $12.5 million when net sales exceed $100 million in a calendar year $20 million when net sales exceed $200 million in a calendar year IPGroup are known to take shares instead of cash on some deals, so they may consider ETON stock as part payment. IPGroup have 29.5% of DNL. That could create the flexibility needed to get a deal together. |
Posted at 12/8/2022 11:23 by deanmatlazin Open Offerand Notice of General Meeting Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, is pleased to announce the completion of the Bookbuild announced earlier today, which was oversubscribed. A total of 28,507,144 Placing Shares have been conditionally placed at the Issue Price of 70 pence per New Ordinary Share alongside a conditional subscription by certain Directors of the Company for 64,285 Subscription Shares, also at the Issue Price, to raise a total of approximately GBP 20.0 million for the Company (before expenses). From April 2021 - Placing 70p/share. Long way for them to recoup the losses. I hope this will come good soon. Nice recovery play |
Posted at 29/6/2022 07:54 by best1467 Could be interesting are Eton lining up a bid for DNL THEY HAVE JUST SOLD RECEIVED $50 Million from sale to India’s DR REddy to solely focus on Rare disease portfolios. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
